- RecruitingPHASE3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
This study is testing a new medicine, lunsekimig, for people with COPD who still have symptoms even with current treatments. It aims to see if lunsekimig is safe and helps improve COPD, particularly for those with a specific type called an 'eosinophilic phenotype'.
For: Chronic Obstructive Pulmonary DiseaseUnited States · Argentina · Australia - Enrolling by invitationPHASE2
Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma
This study is looking at the long-term safety and effectiveness of a new medicine called Lunsekimig for adults with asthma. It's for people who have already taken part in a previous study with this medicine and want to continue their treatment.
For: AsthmaUnited States · Argentina · Brazil - Enrolling by invitationPHASE2
Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study
This study looks at how safe and effective a medicine called lunsekimig is over a long time for adults with long-lasting nose and sinus problems, especially those with nasal polyps, who have already used lunsekimig in a previous study.
For: Chronic Rhinosinusitis With Nasal PolypsUnited States · Argentina · Belgium - Active not recruitingPHASE2
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
This study is looking into a new medication called Lunsekimig for adults with asthma that is hard to control. It compares Lunsekimig to a dummy treatment (placebo) to see if it helps manage asthma better and if it's safe.
For: AsthmaUnited States · Argentina · Belgium - RecruitingPHASE3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
This study is testing a new medicine, lunsekimig, for adults aged 40-80 with COPD that's not well-controlled. We want to see if it helps improve breathing, is safe, and has manageable side effects compared to a dummy medicine.
For: Chronic Obstructive Pulmonary DiseaseUnited States · Argentina · Brazil